business
FDA shuffles top drug, biologics leaders in latest shakeup
Key takeaways
- Livestream Menu Make Itselect USAINTLLivestream Search quotes, news & videos Livestream Watchlist SIGN INCreate free account Markets Business Investing Tech Politics Video Watchlist Investing Club PROLivestream Menu
- Food and Drug Administration is shuffling its top drug and biologics regulators, according to a memo seen by CNBC, days after the departure of former commissioner Marty Makary.
- The two divisions are responsible for regulating prescription drugs, including pills and vaccines.
Livestream Menu Make Itselect USAINTLLivestream Search quotes, news & videos Livestream Watchlist SIGN INCreate free account Markets Business Investing Tech Politics Video Watchlist Investing Club PROLivestream Menu
The U.S. Food and Drug Administration is shuffling its top drug and biologics regulators, according to a memo seen by CNBC, days after the departure of former commissioner Marty Makary.
Acting director of the FDA's Center for Drug Evaluation and Research Tracy Beth Høeg and acting director of the Center for Biologics Evaluation and Research Katherine Szarama will leave their roles, according to the memo. The two divisions are responsible for regulating prescription drugs, including pills and vaccines.
Article preview — originally published by CNBC. Full story at the source.
Read full story on CNBC →
More top stories
Also covered by
Aggregated and edited by the Scoop newsroom. We surface news from CNBC alongside other reporting so you can compare coverage in one place.
Editorial policy · Corrections · About Scoop